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The glucagon-like peptide-1 receptor (GLP1R) is a class B G protein-coupled receptor (GPCR)
involved in metabolism. Presently, its visualization is limited to genetic manipulation, anti-
body detection or the use of probes that stimulate receptor activation. Herein, we present
LUXendin645, a far-red ﬂuorescent GLP1R antagonistic peptide label. LUXendin645 pro-
duces intense and speciﬁc membrane labeling throughout live and ﬁxed tissue. GLP1R sig-
naling can additionally be evoked when the receptor is allosterically modulated in the
presence of LUXendin645. Using LUXendin645 and LUXendin651, we describe islet, brain
and hESC-derived β-like cell GLP1R expression patterns, reveal higher-order GLP1R organi-
zation including membrane nanodomains, and track single receptor subpopulations. We
furthermore show that the LUXendin backbone can be optimized for intravital two-photon
imaging by installing a red ﬂuorophore. Thus, our super-resolution compatible labeling probes
allow visualization of endogenous GLP1R, and provide insight into class B GPCR distribution
and dynamics both in vitro and in vivo.
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The glucagon-like peptide-1 receptor (GLP1R) is a secretinfamily class B G protein-coupled receptor (GPCR) char-acterized by hormone regulation1. Due to its involvement
in glucose homeostasis, the GLP1R has become a blockbuster
target for the treatment of type 2 diabetes mellitus2. The endo-
genous ligand, glucagon-like peptide-1 (GLP-1) is released from
enteroendocrine L-cells in the gut in response to food intake3,
from where it travels to the pancreas before binding to its cognate
receptor expressed in β-cells. Following activation, the GLP1R
engages a cascade of signaling pathways including Ca2+, cAMP,
ERK and β-arrestin, which ultimately converge on β-cell survival
and the glucose-dependent ampliﬁcation of insulin release4,5.
GLP1R is also expressed in the brain6,7, where it further con-
tributes to metabolism via effects on food intake, energy expen-
diture, locomotion, and insulin sensitivity. Despite this, GLP1R
localization remains a challenge and is impeding functional
characterization of GLP-1 and drug action.
Chemical biology and recombinant genetics have made avail-
able a diverse range of methods for the visualization of biological
entities. Thus, classical ﬂuorescent protein-fusions8, self-labeling
suicide enzymes (SNAP-, CLIP-, and Halo-tag)9–11, “click
chemistry”12,13 and ﬂuorogenic probes14–16 have provided insight
into the localization and distribution of their respective targets in
living cells. In particular, current approaches for visualizing the
GLP1R have so far relied on monoclonal antibodies (mAbs)
directed against GLP1R epitopes17,18, SNAP-tags19–21, or ﬂuor-
escent analogues of Exendin4(1–39), Exendin4(9–39), and Lir-
aglutide22–25. Moreover, mouse models exist in which Cre
recombinase is driven by the Glp1r promoter, allowing labeling of
GLP1R-expressing cells when crossed with reporter mice6,7.
Such methods have a number of shortcomings. Antibodies
possess variable speciﬁcity17 and tissue penetration, and GLP1R
epitopes might be hidden or preferentially affected by ﬁxation in
different cell types and tissues. Enzyme self-labels allow GLP1R to
be visualized in living cells without affecting ligand binding, but
require heterologous expression and have therefore not yet been
able to address endogenous receptor. Moreover, ﬂuorescent
analogues of Exendin4(1–39) and Liraglutide activate and inter-
nalize the receptor, which could confound results in live cells,
particularly when used as a tool to sort puriﬁed populations (i.e.
β-cells)26,27. Antagonist-linked ﬂuorophores circumvent this
issue, but the majority lack thorough pharmacological validation,
or possess near infrared tags which require sophisticated confocal
imaging modalities. On the other hand, reporter mouse strategies
possess high ﬁdelity, but cannot account for lineage-tracing
artefacts, post-translational processing, protein stability and
trafﬁcking of native receptor28. Lastly, none of the aforemen-
tioned approaches are amenable to super-resolution imaging of
endogenous GLP1R.
Given the wider reported roles of GLP-1 signaling in the
heart29, liver30, immune system2, and brain31, it is clear that new
tools are urgently required to help identify GLP-1 target sites,
with repercussions for drug treatment and its side effects. In the
present study, we therefore set out to generate a speciﬁc probe for
endogenous GLP1R detection in its native, surface-exposed state
in live and ﬁxed tissue, without receptor activation. Herein, we
report LUXendin645 and LUXendin651, Cy5- and silicon rho-
damine (SiR)- conjugated far-red ﬂuorescent antagonists with
excellent speciﬁcity, live tissue penetration, and super-resolution
capability. Using our tools, we provide an updated view of GLP1R
expression patterns in pancreatic islets, brain, and hESC-derived
β-like cells, show that endogenous GLP1Rs form nanodomains at
the membrane, and reveal receptor subpopulations with distinct
diffusion modes in their non-stimulated state. Lastly, installation
of a tetramethylrhodamine (TMR) ﬂuorophore allows in vivo
multiphoton imaging. As such, the LUXendins provide the ﬁrst
nanoscopic characterization of a class B GPCR, with wider ﬂex-
ibility for detection and interrogation of GLP1R in the tissue
setting both in vitro and in vivo.
Results
Design of LUXendin555, LUXendin645, and LUXendin651.
Ideally, a ﬂuorescent probe to speciﬁcally visualize a biomolecule
should have the following characteristics: straightforward synth-
esis and easy accessibility, high solubility, relatively small size,
high speciﬁcity and afﬁnity, and a ﬂuorescent moiety that exhibits
photostability, brightness and (far-)red ﬂuorescence with an
additional two-photon cross-section. Moreover, the probe should
be devoid of biological effects when applied to live cells and show
good or no cell permeability, depending on its target localization.
While some of these points were addressed in the past, we set out
to achieve this high bar by designing a highly speciﬁc ﬂuorescent
GLP1R antagonist using TMR, Cy5, and SiR ﬂuorophores. As no
small molecule antagonists for the GLP1R are known, we turned
to Exendin4(9–39), a potent antagonistic scaffold amenable to
modiﬁcation (Fig. 1)32. We used solid-phase peptide synthesis
(SPPS) to generate an S39C mutant21, which provides a C-
terminal thiol handle for late-stage installation of different
ﬂuorophores. As such, TMR-, Cy5- and SiR-conjugated versions
were obtained by means of cysteine-maleimide chemistry, termed
LUXendin555, LUXendin645, and LUXendin651, respectively,
with spectral properties shown in Table 1 (characterization of and
purity of compounds in Supplementary Figs. 1–11) (Fig. 1).
LUXendin645 intensely labels GLP1R in cells and tissue. GLP-
1-induced cAMP production was similarly blocked by Exendin4
(9–39) and its S39C mutant (Fig. 2a). Installation of Cy5 to
produce LUXendin645 did not affect these antagonist properties
(Fig. 2a) (Supplementary Fig. 12). No agonist or partial agonist
activity was detected for Exendin4(9–39), S39C_Exendin4(9–39),
or LUXendin645 (Fig. 2a) (Supplementary Fig. 12). As expected,
addition of the GLP1R-positive allosteric modulator (PAM)
BETP33 conferred weak agonist activity on LUXendin645
(EC50(cAMP)= 192 nM) (Fig. 2b).
As a ﬁrst assessment of GLP1R-labeling efﬁciency, we probed
YFP-AD293-SNAP_GLP1R cells with increasing concentrations
of LUXendin645. Maximal LUXendin645 labeling occurred at
250–500 nM (Fig. 2c), with no signal detected in control YFP-
AD293 cells lacking GLP1R (Fig. 2d). We next examined whether
LUXendin645 would allow labeling of endogenous GLP1R in
primary tissue. Following 60 min application of LUXendin645,
isolated islets demonstrated intense and clean labeling, which was
restricted to the membrane (Fig. 2e). To minimize background
ﬂuorescence, slightly lower concentrations of LUXendin645 were
used in islets (50–100 nM) vs. plated cells (250 nM). Using
conventional confocal microscopy, we were able to detect bright
staining even 60 µm into the islet (Fig. 2e). Given these results, we
next attempted to penetrate deeper into the islet by taking
advantage of the superior axial resolution of two-photon
Table 1 Spectral properties of GLP1R labeling probes.
Dye λEx (nm) λEm (nm) ɛa (M−1
cm−1)
Φ
LUXendin555 TMR 555 579 84,000 0.31
LUXendin645 Cy5 645 664 250,000 0.22
LUXendin651 SiR 651 669 100,000 0.43
Maximal excitation and emission wavelengths, and quantum yields were acquired using probes
dissolved at 10 µM in PBS, pH 7.4 at 21 °C
aFor maleimide-conjugated ﬂuorophores
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excitation (Fig. 2f). Remarkably, this imaging modality revealed
LUXendin645 labeling at high resolution throughout the entire
volume of the islet (170 µm in this case) (Fig. 2f). Consistent with
the cAMP assays, GLP1R internalization was detected following
co-application of LUXendin645 and BETP to MIN6 β-cells,
which endogenously express the receptor (Fig. 2g, h).
LUXendin645 allows multiplexed GLP1R detection. Demon-
strating ﬂexibility, LUXendin645 labeling was still present fol-
lowing formaldehyde ﬁxation (Fig. 2i, j). Immunostaining using a
speciﬁc primary monoclonal antibody against the GLP1R
revealed strong co-localization with LUXendin645 in both islets
(Fig. 2i) and MIN6 cells (Fig. 2j). Notably, LUXendin645 dis-
played superior signal-to-noise-ratio and membrane resolution
compared to the antibody (Fig. 2k), expected to be even better in
live tissue where auto-ﬂuorescence is less. Likewise, LUX-
endin645 co-localized with SNAP-Surface 488 in SNAP_GLP1R-
INS1 rat β-cells generated on an endogenous null background
(Fig. 2l). Suggesting that LUXendin645 requires the presence of
surface GLP1R, labeling was markedly reduced following prior
internalization with Exendin4(1–39) (94.1 ± 2.0% decrease in
surface LUXendin645 labelling with Exendin4(1–39) treatment,
mean ± s.d.; n= 3 independent repeats) (Fig. 2l, m).
LUXendin645 speciﬁcally binds the GLP1R. To further validate
the speciﬁcity of LUXendin645 labeling in primary tissue, we
generated Glp1r knock-out mice. This was achieved using
CRISPR-Cas9 genome editing to introduce a deletion into exon 1
of the Glp1r. The consequent frameshift was associated with
absence of translation and therefore a global GLP1R knockout,
termed Glp1r(GE)−/−, in which all intronic regions, and thus
regulatory elements, are preserved (Fig. 3a, b). Wild-type
(Glp1r+/+), heterozygous and homozygous littermates were
phenotypically normal and possessed similar body weights
(Fig. 3c).
Conﬁrming successful GLP1R knock-out, insulin secretion
assays in islets isolated from Glp1r(GE)−/− mice showed intact
responses to glucose, but absence of Exendin4(1–39)-stimulated
insulin secretion (Fig. 3d). Reﬂecting this ﬁnding, the incretin-
mimetic Liraglutide was only able to stimulate cAMP rises in
islets from wild-type (Glp1r+/+) littermates, measured using the
FRET probe Epac2-camps (Fig. 3e, f). As expected, immunostain-
ing with monoclonal antibody showed complete absence of
GLP1R protein (Fig. 3g). Suggesting that LUXendin645 speciﬁ-
cally targets GLP1R, with little to no cross-talk from glucagon
receptors34, signal could not be detected in Glp1r(GE)−/− islets
(Fig. 3g).
Together, these data provide strong evidence for a speciﬁc
mode of LUXendin645 action via the GLP1R.
LUXendin645 highlights weak GLP1R expression. Previous
approaches have shown low abundance of Glp1r transcripts in the
other major islet endocrine cell type, i.e. glucagon-secreting α-
cells7,35. This is associated with detection of GLP1R protein in
~1–10% of cells7,36, providing an excellent testbed for LUX-
endin645 sensitivity and speciﬁcity. Studies in intact islets
showed that LUXendin645 labeling was widespread in the islet
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Fig. 1 Sequence and structure of LUXendin555, LUXendin645, and LUXendin651. LUXendins are based on the antagonist Exendin4(9–39), shown in
complex with GLP1R. The label can be any dye, such as TMR (top), SiR (middle), or Cy5 (bottom) to give LUXendin555, LUXendin645, and LUXendin651,
respectively. The model was obtained by using the cryo-EM structure of the activated form of GLP1R in complex with a G protein (pdb: 5VAI)62, with the G
protein and the 8 N-terminal amino acids of the ligand removed from the structure while mutating S39C and adding the respective linker. Models were
obtained as representative cartoons by the in-built building capability of PyMOL (Palo Alto, CA, USA) without energy optimization. Succinimide
stereochemistry is unknown and neglected for clarity.
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and well co-localized with insulin immunostaining (Fig. 4a).
However, LUXendin645 could also be seen on membranes very
closely associated with α-cells and somatostatin-secreting δ-cells
(Fig. 4b, c), similarly to results obtained with GLP1R mAb. Due to
the close apposition of β-, δ- and α–cell membranes, we were
unable to accurately assign cell-type speciﬁcity to LUXendin645.
Instead, using cell clusters plated onto coverslips, we could better
discern LUXendin645 labeling, revealing GLP1R expression in
12.3 ± 3.3% of α-cells (mean ± s.d.; n= 18 cell clusters, ten ani-
mals, three separate islet preparations) (Fig. 4d–f). Notably,
GLP1R-expressing α-cells tended to adjoin, whereas those with-
out the receptor were next to β-cells. Conﬁrming previous ﬁnd-
ings, a majority (85.1 ± 16.3%) (mean ± s.d.; n= 18 cell clusters,
ten animals, three separate islet preparations) of β-cells were
positive for LUXendin645 (Fig. 4d–f)7,25.
We wondered whether ﬁxation required for immunostaining
might increase background ﬂuorescence such that GLP1R
detection speciﬁcity was reduced. To circumvent this, studies
were repeated in live islets where LUXendin645 signal was found
to be much brighter and background almost non-existent. GLP1R
was detected in 24.6 ± 5.0% (mean ± s.d.; n= 31 islets, six
animals, three separate islet preparations) of non-β-cells (Fig. 4g,
h) using Ins1CreThor;R26mTmG reporter mice in which β-cells are
labeled green and all other cell types are labeled red following
Cre-mediated recombination. Once adjusted for the previously
reported GLP1R expression in δ-cells (assuming 100%), which
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constitute ~20% of the insulin-negative islet population37, this
leaves ~5% of GLP1R+ α-cells. This was not an artefact of optical
section, since two-photon islet reconstructions showed similar
complete absence of LUXendin645 staining in discrete regions
near the surface (where α-cells predominate) (Supplementary
Movie 1).
LUXendins reveal higher-order GLP1R organization. By
combining LUXendin645 with super-resolution radial ﬂuctua-
tions (SRRF) analysis38, GLP1R could be imaged at super-
resolution using streamed images (~500) from a conventional
wideﬁeld microscope (Fig. 5a). To image endogenous GLP1R at
<100 nm lateral resolution, we combined STED nanoscopy with
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LUXendin651, which bears SiR instead of Cy5. LUXendin651
displayed antagonist behavior, with no evidence of partial agon-
ism, and produced bright labeling of wild-type but not Glp1r
(GE)−/− islets, with an identical distribution to LUXendin645
(Supplementary Figs. 12 and 13). Incubation of MIN6 cells with
LUXendin651 and subsequent ﬁxation allowed STED imaging
of the endogenous GLP1R with a FWHM= 70 ± 10 nm (mean ±
s.d.; n= 15 line proﬁles measured on the raw data, from two
independent repeats) (Fig. 5b–d). STED snapshots of MIN6 β-
cells revealed detailed GLP1R distribution: receptors were not
randomly arranged but rather tended to organize into nanodo-
mains with neighbors (Fig. 5b–d). This was conﬁrmed using the
F- and G-functions, which showed a non-random and more
clustered GLP1R distribution (Fig. 5e, f). Differences in GLP1R
expression level and pattern could clearly be seen between
neighboring cells with a subpopulation possessing highly con-
centrated GLP1R clusters (Fig. 5g). LUXendin651 even allowed
GLP1R to be imaged in living MIN6 cells using SRRF and STED,
although nanodomains were more difﬁcult to resolve due to the
lateral diffusion of receptors (Fig. 5h, i).
LUXendin645 and Luxendin651 label single GLP1R molecules.
To test whether LUXendin645 and LUXendin651 would be
capable of tracking single GLP1Rs in live cells, we performed
single-molecule microscopy experiments in which individual
receptors labeled with either ﬂuorescent probe were imaged by
total internal reﬂection ﬂuorescence (TIRF) microscopy39,40. Both
probes allowed GLP1R to be tracked at the single-molecule level
in CHO-K1-SNAP_GLP1R cells, but bleaching precluded longer
recordings with LUXendin645 (Fig. 6a and Supplementary
Movies 2, 3). By combining single-particle tracking with LUX-
endin651, we were able to show that GLP1Rs diffuse at the
membrane in their non-stimulated or antagonized state (Fig. 6a
and Supplementary Movie 4). However, a mean square dis-
placement (MSD) analysis40 revealed a high heterogeneity in the
diffusion of GLP1Rs on the plasma membrane, ranging from
virtually immobile receptors to some displaying features of
directed motion (superdiffusion) (Fig. 6b, c). GLP1R diffusion
properties were not ligand-dependent, since similar proﬁles were
detected for both LUXendin645 and LUXendin651 (Fig. 6c).
LUXendin645 allows visualization of central GLP1 targets. To
further show the utility of LUXendin645 for visualizing endo-
genous GLP1R, we extended studies to the brain in which mAbs
do not work reliably and where peripheral GLP1 targets still
remain poorly characterized. Two hours following subcutaneous
injection of LUXendin645, perfuse-ﬁxed brains were retrieved for
analysis. Intense labelling could be detected in the arcuate nucleus
(ARC), area postrema (AP) and choroid plexus (CP) (Fig. 7a, b),
all regions known to express GLP1R using reporter or ﬂuorescent
agonist approaches6,22. Notably, LUXendin645-labeled neurons
overlapped with areas receiving innervation from GLP1-
producing neurons41, with GLU-YFP synaptic boutons closely
abutting GLP1R+ areas (Fig. 7a, b). LUXendin645 labeling co-
localized with GLP1R-expressing neurons in the ARC/median
eminence (ME) and AP/nucleus tractus solitarius (NTS), shown
using GLP1RCre;LSL-GCaMP3 reporter mice (Fig. 7c–e).
Super-resolution imaging (~140 nm lateral resolution) revealed
the presence of LUXendin645 on the cell membranes of GLP1R+
neuron cell bodies, as well as dendrites. Moreover, GLP1R were
found to accumulate into nanodomains on the membranes of
ARC and AP neuron membranes, as well as ependymal cells of
the CP (Fig. 7f). Lastly, optical projection tomography allowed
entire LUXendin645-labelled brains to be imaged and mapped in
three-dimensions, conﬁrming the above results and also extend-
ing probe localization to the subfornical organ (SFO), organum
vasculosum of the lamina terminalis (OVLT), and ventricles
(Fig. 7g).
LUXendin645 labels GLP1R in hESC-derived β-cells. Since
GLP1R are expressed in mature β-cells42, we wondered whether
LUXendin645 would serve as a useful surface marker for
assessing differentiation of human embryonic stem cell (hESC)-
derived β-like cells. LUXendin645 was unable to label undiffer-
entiated ES cells (Fig. 8a). Following differentiation and 21 days’
culture, LUXendin645 labeling was clearly visible in spheroids, in
line with increasing levels of GLP1R expression (Fig. 8b). As for
mouse islets, LUXendin645 co-localized with insulin, with
minimal signal in areas strongly positive for glucagon (Fig. 8c),
shown using Manders’ split coefﬁcients (Fig. 8d). Not all insulin-
containing cells stained for GLP1R, however (Fig. 8c). Conﬁrm-
ing a β-like cell phenotype, spheroids were ﬁxed and sliced before
staining for insulin and NKX6-1 (Fig. 8e).
We next investigated whether LUXendin645 would allow β-
like cells to be puriﬁed according to GLP1R expression. To this
end, LUXendin645-labelled spheroids were subjected to
ﬂuorescence-activated cell sorting (FACS), before gene expression
analyses of LUXendin645+ and LUXendin645− populations.
Notably, the LUXendin645+ population expressed higher levels
of GLP1R and NKX6-1, with a tendency toward increased INS
(Fig. 8f). As expected from the imaging data, GCG expression was
signiﬁcantly decreased in the LUXendin645+ β-like cells
(Fig. 8f).
LUXendin555 allows labeling of islets in vivo. Lastly, we
explored whether swapping the far-red Cy5/SiR for a TMR dye
would be tolerated to obtain a spectrally orthogonal probe,
Fig. 3 LUXendin645 is highly speciﬁc for the GLP1R. a Schematic showing sgRNA-targeting strategy for the production of Glp1r(GE)−/− mice. The sgRNA
used targeted Glp1r and the double-strand break mediated by Cas9 lies within exon1 (capital letters); intron shown in gray. b Glp1r(GE)−/− animals harbor a
single-nucleotide deletion, as shown by sequencing traces. c Body weights were similar in male 8–9 weeks old Glp1r+/+, Glp1r(GE)+/−, and Glp1r(GE)−/−
littermates (n= 9 animals) (one-way ANOVA with Bonferroni’s test; F= 0.362, DF= 2). d The incretin-mimetic Exendin4(1–39) (Ex4; 10 nM) is unable to
signiﬁcantly potentiate glucose-stimulated insulin secretion in Glp1r(GE)−/− islets (n= 15 repeats, six animals for each genotype, three separate islet
preparations) (between genotype comparisons: two-way ANOVA with Sidak’s test; F= 4.061, DF= 2) (within genotype comparisons: one-way ANOVA
with Bonferroni’s post-hoc test; F= 14.57 (Glp1r+/+), 10.83 (Glp1r(GE)−/−); DF= 2). e Liraglutide (Lira) does not stimulate cAMP beyond vehicle (Veh)
control in Glp1r(GE)−/− islets, measured using the FRET probe Epac2-camps (n= 25 islets for each genotype, three animals per genotype, two separate islet
preparations). f cAMP area-under-the-curve (AUC) quantiﬁcation showing absence of signiﬁcant Liraglutide-stimulation in Glp1r(GE)-/- islets (n= 25 islets
for each genotype, three animals per genotype, two separate islet preparations) (Kruskal–Wallis test with Dunn’s test; Kruskal–Wallis statistic= 31.78,
DF= 2) (Box and Whiskers plot shows range and median) (representative images displayed above each bar; color scale shows min to max values as a
ramp from blue to red). g LUXendin645 and GLP1R antibody labeling is not detectable in Glp1r(GE)−/− islets (scale bar= 40 µm) (n= 27 islets, ﬁve animals
per genotype, three separate islet preparations). For all statistical tests, *P < 0.05, **P < 0.01 and NS, non-signiﬁcant. In all cases, LUXendin645 was
applied at 100 nM. Mean ± s.e.m. are shown. Source data are provided as a Source Data ﬁle.
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termed LUXendin555. Labeling was detected in YFP-AD293-
SNAP_GLP1R (Fig. 9a) but not in YFP-AD293 cells (Fig. 9b),
with max labeling at 600 nM (Fig. 9c). A slightly lower con-
centration (250 nM) of LUXendin555 was found to produce
bright staining in both cells and islets, whilst minimizing back-
ground ﬂuorescence. However, we noticed a more punctate
LUXendin555 staining pattern when viewed at high-resolutions
(Fig. 9a). To determine whether the appearance of puncta was
due to receptor internalization, or alternatively accumulation of
cleaved, charged TMR in organelles, labeling was repeated in
islets co-stained with GLP1R monoclonal antibody (Supplemen-
tary Fig. 14). In these experiments, no differences in GLP1R
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surface expression could be seen between LUXendin555, LUX-
endin645, and Ex9 (Fig. 9d), suggesting that puncta are unlikely
to be internalized receptor. In line with this, LUXendin555 was
found to display antagonist properties using HTRF-based cAMP
assay (Fig. 9e). However, a second independent detection method
(luciferase) showed the opposite result, raising the possibility that
the installed TMR might inﬂuence assay readout (Fig. 9f). As for
the other probes, LUXendin555 was unable to label Glp1r(GE)−/−
islets (Supplementary Fig. 14).
We thought that the relatively high quantum yield of TMR,
coupled with good two-photon cross-section might suit LUX-
endin555 well to in vivo imaging. Two-photon imaging was
applied to anaesthetized mice to allow visualization of the intact
pancreas, exposed through an abdominal incision (Fig. 9g).
Vessels and nuclei were ﬁrst labeled using FITC-dextran and
Hoechst before injecting LUXendin555 intravenously. The
following observations support that LUXendin555 displays
antagonist activity in vivo: (1) labeling occurred rapidly within
5 min post-injection; (2) staining was conﬁned to the cell
membrane with no apparent internalization (Fig. 9h); and (3)
normoglycemia was not signiﬁcantly altered over 30 min (173.0 ±
21.1 vs. 215.3 ± 41.4 mg/dl, 0 and 30 min post-injection, respec-
tively; mean ± s.d.; n= 3 mice; non-signiﬁcant, paired t-test).
Discussion
In the present study, we synthesize and validate far-red ﬂuor-
escent labels, termed LUXendins for the real-time detection of
endogenous GLP1R in live cells. Nanomolar concentrations of
LUXendin645 and LUXendin651 lead to intense membrane-
labeling of the GLP1R, with best in class tissue penetration and
signal-to-noise ratio, as well as super-resolution capability.
Notably, LUXendin645 and LUXendin651 do not activate the
GLP1R unless agonist activity is conferred with the widely
available PAM BETP. LUXendin645 and LUXendin651 are
highly speciﬁc, as shown using a CRISPR-Cas9 mouse line lacking
GLP1R expression. Lastly, the analogous compound LUX-
endin555, bearing a different ﬂuorophore, expands the color
palette without changing the peptidic pharmacophore.
Compared to present chemical biology approaches, LUX-
endins possess a number of advantages for GLP1R labeling,
which generally rely on Exendin4(1–39) or Exendin4(9–39)
peptides labeled with for instance FITC, Cy3, Alexa594, Cy5, or
VT75019,22–25,33. Firstly, the use of an antagonist retains more
receptor at the cell surface, which likely increases detection cap-
ability. Secondly, the GLP1R is not fully activated, meaning that
results can be interpreted in the absence of potentially con-
founding cell signaling or internalization, such as that expected
with agonists25. Thirdly, Cy5 and SiR occupy the far-red range,
leading to less background ﬂuorescence, increasing depth pene-
tration in confocal microscopy due to reduced scatter, and
avoiding the use of more phototoxic wavelengths43. Fourthly,
LUXendin pharmacology and labelling speciﬁcity has been vali-
dated in-depth. Lastly, LUXendins are well-adapted for super-
resolution imaging through the use of optimally suited ﬂuorescent
moieties. Together, these desirable properties open up the pos-
sibility to image expression and distribution of native GLP1R over
extended periods of time using multiple imaging modalities.
While LUXendins also allowed GLP1R trafﬁcking to be
monitored, this required the presence of a PAM to allosterically
activate the receptor. Due to the probe-dependent nature of
PAMs, LUXendins with a number of different pharmacophores
would need to be generated to fully assess the ligand-dependency
of GLP1R trafﬁcking. In some experiments, we also noticed the
presence of punctate LUXendin645 and LUXendin651 labelling.
Suggesting that this staining pattern reﬂects cleaved ﬂuorophore
rather than internalized GLP1R are the following observations:
(1) succinimide exchange with reactive thiols can lead to linker
loss44, allowing free ﬂuorophore to cross the membrane and
accumulate in organelles; and (2) puncta were not apparent in the
same samples co-stained with GLP1R mAb.
To test the speciﬁcity of LUXendins, we used CRISPR-Cas9
genome-editing to globally knock out the GLP1R in mice. Protein
deletion was conﬁrmed by absence of detectable GLP1R signal
following labeling with monoclonal antibody, LUXendin555,
LUXendin645, and LUXendin651. While Glp1r−/− animals
already exist, and have made important contributions to our
understanding of incretin biology, they were produced using a
mutation to replace exons encoding transmembrane regions 1
and 3 (encoded by exons 5 and 7), presumably leading to deletion
of the introns in between (~6.25 kb)45. By contrast, Glp1r(GE)−/−
mice possess intact introns. Since introns contain regulatory
elements, such as distant-acting enhancers46, miRNAs47, and
lncRNAs48, their loss in transgenic knockouts could have wider
inﬂuence on the transcriptome. GLP1R knock-out mice might
therefore be useful alongside conventional approaches for vali-
dating GLP1R reagents, including antibodies, agonist and
antagonist, and derivatives thereof.
Demonstrating the excellent sensitivity of the Cy5-linked
LUXendin645 in particular, we were able to detect GLP1R
expression in ~5% of α-cells. Understanding α-cell GLP1R
expression patterns is important because incretin-mimetics
reduce glucagon secretion49, which would otherwise act to
aggravate blood glucose levels. Previous studies using antibodies,
reporter animals and agonist-ﬂuorophores have shown that
~1–10% of mouse and rat α-cells express GLP1R, in line with the
low transcript abundance7,25,35,50, despite reports that GLP-1 can
directly suppress glucagon release36. Our data are in general
concordance with these ﬁndings, but demonstrate an increase in
sensitivity compared to other approaches capable of detecting
native GLP1R protein, namely mAb and agonist-ﬂuorophore.
This improvement is likely related to the superior signal-to-noise
ratio (SNR) and selectivity of LUXendin645, increasing the
Fig. 4 LUXendin645 reveals GLP1R expression in a subpopulation of α-cells. a–c LUXendin645 labeling is widespread throughout the intact islet, co-
localizing predominantly with β-cells a and δ-cells b, but less so with α-cells c stained for insulin (INS), somatostatin (SST), and glucagon (GCG),
respectively (n= 18 islets, seven animals, three separate islet preparations) (scale bar= 26 µm). d Following dissociation of islets into cell clusters,
LUXendin645 labeling can be more accurately quantiﬁed (arrows highlight cells selected for zoom-in) (scale bar= 26 µm). e Zoom-in of d showing a
LUXendin645− (left) and LUXendin645+ (right) α-cell (arrows highlight non-labeled cell membrane, which is not bounded by a β-cell) (scale bar=
26 µm). f Box-and-whiskers plot showing proportion of β-cells (INS) and α-cells (GCG) co-localized with LUXendin645 (n= 18 cell clusters, ten animals,
three separate islet preparations) (box and whiskers plot shows range and median; mean is shown by a plus symbol). g Ins1CreThor;R26mT/mG dual
ﬂuorophore reporter islets express tdTomato until Cre-mediated replacement with mGFP, allowing identiﬁcation of β-cells (~80% of the islet population)
and non-β-cells for live imaging (scale bar= 26 µm). LUXendin645 (LUX645) highlights GLP1R expression in nearly all β-cells but relatively few non-β-
cells (n= 31 islets, six animals, three separate islet preparations). h A zoom-in of the islet in g showing GLP1R expression in some non-β-cells (left)
together with quantiﬁcation (right) (arrows show LUXendin645-labeled non-β cells) (scale bar= 12.5 µm) (scatter dot plot shows mean ± s.e.m.). White
boxes show the location of zoom-ins. In all cases, LUXendin645 was applied at 100 nM. Source data are provided as a Source Data ﬁle.
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ability to resolve relatively low levels of endogenous GLP1R. A
recent report showed GLP1R expression in ~80% of α-cells using
an antibody raised against the N-terminal region, with both
membrane and cytosolic staining evident51. While the reasons for
this discrepancy are unknown, it should be noted that
LUXendin645 binds the orthosteric site and so reports the pro-
portion of GLP1R that is “signaling competent”7,19,32.
In addition to islets, LUXendin645 was also able to label brain
tissue. 3D rendering of entire cleared brains using optical pro-
jection tomography showed strong LUXendin645 staining in the
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circumventricular organs and their directly neighboring regions,
including the NTS and ARC. We also detected LUXendin645-
labelling in the CP, an epithelial-vascular structure that secretes
cerebrospinal ﬂuid (CSF). Rat CP has recently been shown to
express GLP1R ex vivo, with Ex4 reducing intracranial pressure
in hydrocephalic models52. Notably, super-resolution snapshots
showed that GLP1R in the ARC, AP, and CP were organized
as nanodomains at the membrane. Such higher organization
has not been previously appreciated in the brain and it will
now be interesting to understand the functional relevance for
GLP1 signaling. A number of central GLP1R-expressing regions
remained obscure, likely reﬂecting the pharmacokinetic proper-
ties of peripherally administered agonist/antagonist. However, we
anticipate that LUXendin645 will be useful for the study of these
Fig. 5 LUXendin651 and LUXendin645 allow nanoscopic detection of GLP1R. a LUXendin645 allows super-resolution snapshots of MIN6 β-cells using
wideﬁeld microscopy combined with super-resolution radial ﬂuctuations (SRRF) (representative image from n= 8 images, three independent repeatss)
(scale bar= 10 µm for full-ﬁeld images, 2.5 µm for zoomed-in images). b–d Confocal and STED snapshots of endogenous GLP1R in LUXendin651-treated
MIN6 cells at FWHM= 70 ± 10 nm (mean ± s.d.; n= 15 line proﬁles measured on the raw data, two independent repeats). Note the presence of
punctate GLP1R expression as well as aggregation/clustering in cells imaged just away from b, close to c or next to d the coverslip using STED
microscopy (representative image from n= 8 images, three independent repeats) (scale bar= 2 µm for full-ﬁeld images, 1 µm for zoomed-in images).
e, f Representative graph showing spatial analysis of GLP1R expression patterns using the F-function e and G-function f, which show distribution (red line)
vs. a random model (black line; 95% conﬁdence interval shown) (n= 6 from three independent repeats). g Approximately 1 in 4 MIN6 β-cells possess
highly concentrated GLP1R clusters. h, i LUXendin651 allows GLP1R to be imaged in living MIN6 cells using SRRF h and STED i (representative image from
n= 6 and 18 images, three independent repeats for SRRF and STED, respectively) (scale bar= 10 µm for full-ﬁeld SRRF image, 2.5 µm for the zoomed-in
image) (scale bar= 2 µm for STED images). White boxes show the location of zoom-ins. The following compound concentrations were used: 100 nM
LUXendin645 (SRRF) and 100–400 nM LUXendin651 (STED). Mean ± s.e.m. are shown. Source data are provided as a Source Data ﬁle.
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Fig. 6 LUXendin645 and LUXendin651 allow single molecule GLP1R imaging. a Representative single molecule microscopy images showing tracking of
LUXendin645- and LUXendin651-labeled GLP1R at or close to the membrane (scale bar= 3 µm). b Mean square displacement (MSD) analysis showing
different GLP1R diffusion modes (representative trajectories are displayed) (scale bar= 1 µm). c GLP1R molecules with diffusion coefﬁcient D < 0.01 are
classed as immobile (left), whilst those with D > 0.01 are further divided according to their anomalous diffusion exponent (α), which deﬁnes the type of
motion followed (conﬁned, normal, or directed) (right) (pooled data from n= 16 cells, 5057–8612 trajectories, six independent repeats). LUXendin645 and
LUXendin651 were used at 100 pM. Source data are provided as a Source Data ﬁle.
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regions following targeted injections. Taken together, these data
show that LUXendin645 allows endogenous GLP1R to be
visualized in extrapancreatic tissue using both conventional and
super-resolution-imaging approaches.
We could also extend studies to hESC-derived β-like cells,
where GLP1R expression was detected in spheroids following
induction of differentiation and 21 days’ culture. LUXendin645
labeling was seen almost exclusively in the β-like cell compart-
ment, reﬂecting known distributions in mouse7,25 and human53
islets. While not all β-like cells were visibly labelled, this likely
reﬂects GLP1R expression levels, which were ~50% lower in
spheroids than adult human islets. Pertinently, LUXendin645
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allowed more mature/differentiated β-like cells to be identiﬁed
and puriﬁed according to GLP1R, which increases almost 20-fold
in adult vs. neonatal rat β-cells42. Thus, these studies show the
potential of LUXendins to understand GLP1R expression pat-
terns in regenerated β-like cells, as well as rapidly mark differ-
entiation/maturity status using a simple one-step surface marker.
Since LUXendin645 showed excellent SNR using conventional
epiﬂuorescence, it was highly amenable to SRRF analysis. As
such, LUXendin645 and its congeners open up the possibility to
image the GLP1R at super-resolution using simple wideﬁeld
microscopy available in most laboratories. For stimulated emis-
sion depletion (STED) microscopy experiments, Cy5 was
replaced with SiR to give LUXendin651. STED imaging showed
that endogenous GLP1R possess a higher structural order in the
presence of LUXendin651 binding: namely organization into
nanodomains at the cell membrane. Since GLP1R plasma mem-
brane distribution is ligand-dependent, for example via effects on
palmitoylation and clustering into cholesterol-rich nanodo-
mains20 it will be interesting to repeat these experiments using a
range of agonists/antagonists. Indeed, LUXendins provide an
ideal template for the production of ﬂuorescent ligands that
would allow super-resolution examination of nanodomain
architecture in response to different activation modes.
Notably, a subpopulation of β-cells appeared to possess con-
centrated GLP1R clusters even in unstimulated conditions. It will
be important in the future to investigate whether this is a cell
autonomous heterogenous trait, or instead reﬂects biased dis-
tribution of receptors in membranes of speciﬁc β-cells. Lastly,
both LUXendin645 and LUXendin651 allowed GLP1Rs to be
imaged in live cells by single molecule microscopy, revealing
variability in diffusion at the plasma membrane. Particle tracking
analyses segregated GLP1R into four different populations based
upon diffusion mode, in keeping with data from a class A GPCR,
the beta adrenergic receptors40. Together, these experiments
provide the ﬁrst super-resolution characterization of a class B
GPCR and suggest a degree of complexity not readily appreciated
with previous approaches.
LUXendin555 showed antagonist activity in terms of cAMP
generation using a HTRF approach. However, we could not
conﬁrm this result using a luciferase-based detection method. The
reasons for this are unclear, but might include interference of the
red ﬂuorescent TMR with either assay, or alternatively different
GLP1R coupling strength between cell lines. As such, use of
LUXendin555 should consider the possibility that the ligand is an
antagonist or agonist. Nonetheless, LUXendin555 retained
GLP1R at the membrane, and possesses advantageous properties
for in vivo imaging including good two-photon cross-section and
high quantum yield.
In summary, we provide a comprehensively tested and unique
GLP1R detection toolbox consisting of far-red antagonist labels,
LUXendin645 and LUXendin651, an agonist/antagonist LUX-
endin555, and knockout Glp1r(GE)−/− animals. Using these freely
available probes, we provide an updated view of GLP1R organi-
zation, with relevance for the treatment of complex metabolic
diseases such as obesity and diabetes. Thus, the stage is set for
visualizing GLP1R in various tissues using a range of imaging
techniques, as well as the production of peptidic labels and agonists.
Methods
Synthesis. A free cysteine bioconjugation handle was installed on Exendin4(9–39)
using solid-phase synthesis to give the derivatized S39C-Exendin4(9–39)21. Mal-
eimide-conjugated-6-TMR, -6-SiR and -Cy5 were obtained by TSTU activation of
the corresponding acids and reaction with 1-(2-amino-ethyl)-pyrrole-2,5-dione
(TFA salt, Aldrich). Fluorophore coupling via thiol-maleimide chemistry to pep-
tides was performed in PBS. All compounds were characterized by HRMS and
purity was assessed to be >95% by HPLC. Extinction coefﬁcients were based upon
known manufacturer bulk material measures for TMR-Mal, Cy5-Mal (both
Lumiprobe), and SiR-Mal (Spirochrome). Details for synthesis including char-
acterization of all LUXendins are detailed in the Supplementary Methods and
Supplementary Figs. 1–11. LUXendin555, LUXendin645, and LUXendin651 are
freely available for academic use upon request.
Cell culture. AD293 cells (Agilent) were maintained in Dulbecco’s Modiﬁed Eagles
medium (DMEM; D6546, Sigma) supplemented with 10% fetal calf serum (FCS),
1% L-glutamine, and 1% penicillin/streptomycin. CHO-K1 cells stably expressing
the human SNAP_GLP1R (Cisbio) (CHO-K1-SNAP_GLP1R) were maintained in
DMEM supplemented with 10% FCS, 1% penicillin/streptomycin, 500 μg/mL
G418, 25 mM HEPES and 1% nonessential amino acids and 2% L-glutamine. MIN6
β-cells (a kind gift from Prof. Jun-ichi Miyazaki, Osaka University) were main-
tained in DMEM (D6546, Sigma) supplemented with 15% FCS, 25 mM D-glucose,
71 μM BME, 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin,
and 25 mM HEPES. INS1 832/3 CRISPR-deleted for the endogenous GLP1R locus
(a kind gift from Dr. Jacqui Naylor, MedImmune)54 were transfected with human
SNAP_GLP1R, before FACS of the SNAP-Surface488-positive population and
selection using G41820. The resulting SNAP_GLP1R_INS1GLP1R−/− cells were
maintained in RPMI-1640 supplemented with 10% FBS, 10 mM HEPES, 2 mM L-
glutamine, 1 mM pyruvate, 72 µM β-mercaptoethanol, 1% penicillin/streptomycin,
and 500 μg/mL G418.
Animals. Glp1r(GE)-/-: CRISPR-Cas9 genome-editing was used to introduce a single
base pair deletion into exon 1 of the Glp1r locus. Fertilized eggs of female Cas9-
overexpressing mice (strain Gt(ROSA)26Sortm1.1(CAG-cas9*,–EGFP)Fezh/J; JAX stock
no. 024858) were harvested following super-ovulation. Modiﬁed single-guide RNA
(Synthego) targeting exon 1 of Glp1r and a single-stranded repair-template were
injected at 20 ng/µl into the pronucleus of embryos at the 1-cell stage. In culture,
80% of embryos reached the 2-cell stage and were transplanted into surrogate mice.
Glp1r(GE)−/− mice did not integrate the repair-template (conﬁrmed by genotyping
PCR), but instead harbored a single nucleotide deletion leading to a frame-shift
mutation and loss of GLP1R protein. Knock-in mice that integrated the repair
template were not used in the present studies and will be described elsewhere. The
targeted locus of Glp1r(GE)−/− offspring was analyzed by PCR and sequencing. Off-
target sites were predicted using the CRISPR Guide Design Tool (crispr.mit.edu).
Loci of the top 10 off-target hits were ampliﬁed by PCR and analyzed via Sanger
sequencing (Supplementary Table 1). Founder animals carrying alleles with small
deletions were backcrossed to wild type animals (strain C57BL/6J) for 1–3 gen-
erations to outbreed affected off-targets and then bred to homozygosity (Supple-
mentary Figs. 15 and 16). Animals were born in Mendelian ratios, genotyping was
performed using Sanger sequencing or PCR. Genotyping PCRs were performed
Fig. 7 LUXendin645 highlights GLP1R-expressing neurons in the brain. a LUXendin645 labeling is detected in the the median eminence (ME), arcuate
nucleus (ARC), area postrema (AP)/nucleus tractus solitaris (NTS), and choroid plexus (CP), in close association with GLP1-producing neurons, identiﬁed
using GLU-YFP reporter animals (3V, third ventricle) (representative images from n= 4 animals) (scale bar= 106 µm). b Z-projection of an image stack
(~30 µm) showing direct contacts between LUXendin645-labelled and GLP1-producing (GLU-YFP) neurons in the ARC (representative image from n= 4
animals) (scale bar= 20 µm). c, d LUXendin645 labeling co-localizes with GLP1R+ neurons in the AP/NTS c and ARC d, identiﬁed using GLP1RCre;LSL-
GCaMP3 reporter animals (representative image from n= 4 animals) (scale bar= 61 µm). e Super-resolution imaging using Airyscan shows that
LUXendin645 labeling is restricted to the membrane of the cell body and dendrites of GLP1R+ neurons (arrows show cell body and dendrite from left to
right, respectively) (representative images from n= 4 animals) (scale bar= 9 µm). f GLP1R form nanodomains in ARC and AP neurons, as well as
ependymal cells of the CP (confocal image is shown on the left for comparison) (representative images from n= 8 animals) (scale bar= 9 µm). gMapping
of LUXendin645 distribution in cleared brains shows labelling of the ARC, AP/NTS, CP, lateral ventricles (LV), fourth ventricle (4V), subfornical organ
(SFO), and organum vasculosum of the lamina terminalis (OVLT) (representative images from n= 4 animals) (scale bar= 1 mm). Note that, due to
suspension of the brain, the coronal section is slightly offset in the dorsal–ventral plane; hence, the SFO appears above the ARC. In all cases, LUXendin645
was injected subcutaneously at 100 pmol/g.
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with Glp1r forward primer 5′-CAGGCGCTCAGAGCTAGAAGC-3′ and with
Glp1r wild-type reverse primer 5′-CCAGGGCTCACCTGAGGG-3′ or Glp1r
knockout 5′-CCAGGGCTCACCTGAGGC-3′ to amplify and detect the WT or
mutant allele, respectively. Animals were bred as heterozygous pairs to ensure
Glp1r+/+ littermates. Glp1r(GE)−/− animals are freely available for academic use,
subject to a Material Transfer Agreement.
Ins1CreThor;R26mT/mG: To allow identiﬁcation of β- and non-β-cells, Ins1CreThor
animals with Cre knocked-in at the Ins1 locus (strain B6(Cg)-Ins1tm1.1(cre)Thor/J;
JAX stock no. 026801) were crossed with R26mT/mG reporter mice (strain B6.129
(Cg)-Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J; JAX stock no. 007676). Cre-
dependent excision of the ﬂoxed allele results in deletion of tdTomato, expression
of membrane-localized GFP and thus identiﬁcation of recombined and non-
recombined cells.
GLU-YFP: Animals harboring YFP under the control of the glucagon promoter
were generated and bred as previously described55.
GLP1RCre;LSL-GCaMP3: To identify GLP1R-expressing cells in the brain, mice
with Glp1r promoter-drive Cre7 were bred with stop-ﬂox’d GCaMP3 animals (JAX
stock no. 014538).
CD1 wild-type animals were purchased from Charles River Laboratories UK.
All studies were performed with 6–12-week-old male and female animals,
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Ethical approval. All animal research complied with the Animals (Scientiﬁc
Procedures) Act 1986 of the U.K. Approval was granted by the University of
Birmingham’s Animal Welfare and Ethical Review Body. Procurement of human
islets was approved by the Human Research Ethics Board (Pro00013094;
Pro00001754) at the University of Alberta and all families of organ donors pro-
vided written informed consent. hESC (WA01/H1; hPSCreg name WAe001-A)
(obtained from WiCell) were generated by the originating institute with informed
consent and ethical approval from the Robert-Koch Institut, Berlin (Az.3.04.02/
0101) and NIH (NIHhESC-10-0043). Studies with hESC (WA01/H1) were
approved by the BC Children’s and Women’s Hospital Human Research Ethics
Board (Approval #H09-00676). Studies with human tissue were approved by the
BC Children’s and Women’s Hospital Human Research Ethics, University of
Birmingham Ethics Committee and the National Research Ethics Committee (REC
reference 16/NE/0107, Newcastle and North Tyneside, UK).
Islet isolation. Animals were humanely euthanized before injection of collagenase
1 mg/mL (Serva NB8) into the bile duct. Following removal of the inﬂated pancreas
and digestion for 12 min at 37 °C, islets were separated using a Histopaque (Sigma-
Aldrich) gradient. Islets were cultured in RPMI medium containing 10% FCS,
100 units/mL penicillin, and 100 μg/mL streptomycin.
Binding and potency assays. Binding assays were performed in transiently
transfected YFP-AD293-SNAP_GLP1R cells (using PolyJet reagent; SignaGen).
Increasing concentrations of compound were applied for 60 min, before imaging
using a Zeiss LSM880 meta-confocal microscope conﬁgured with GaAsP detectors
and ×10/0.45W, ×40/1.00W and ×63/1.20W objectives. YFP, TMR (LUX-
endin555), and Cy5 (LUXendin645) were excited using λ= 514 nm, λ= 561 nm,
and λ= 633 nm lasers, respectively. Emitted signals were captured at λ=
519–574 nm, λ= 570–641 nm, and λ= 638–759 nm for YFP, TMR (LUX-
endin555), and Cy5 (LUXendin645), respectively. Control experiments were
performed in YFP-AD293-SNAP cells, as above.
Potency for cAMP generation and inhibition was tested in heterologous
expression systems, comprising either stable CHO-K1-SNAP_GLP1R or HEK-
SNAP_GLP1R cells, or transiently transfected YFP-AD293-SNAP_GLP1R cells21.
Brieﬂy, cells were incubated with increasing concentrations of compound with and
without allosteric modulator for 30 min, before harvesting, lysis and measurement
of cAMP using either cAMP-GloTM (Promega) or HTRF (Cisbio) assays, according
to the manufacturer’s instructions. All assays were performed in the presence of
100–500 µM IBMX to inhibit phosphodiesterase activity. EC50 values were
calculated using log concentration–response curves ﬁtted with a three-parameter or
four-parameter equation.
Live imaging. Islets were incubated for 1 h at 37 °C in culture medium supple-
mented with either 100–250 nM LUXendin555, 50–100 nM LUXendin645, or
100 nM LUXendin651. Islets were imaged using either a Zeiss LSM780 or LSM880
microscope, as above (LUXendin651 was imaged as for LUXendin645).
Ins1CreThor;R26mT/mG islets were excited at λ= 488 nm (emission, λ=
493–555 nm) and λ= 561 nm (emission, λ= 570–624 nm) for mGFP and tdTo-
mato, respectively. Two-photon imaging of LUXendin645 was performed using a
Zeiss LSM 880 NLO equipped with a Spectra-Physics Insight X3 femtosecond-
pulsed laser and ×20/1.00W objective. Excitation was performed at λ= 800 nm and
emitted signals detected at λ= 638–759 nm.
cAMP imaging. Islets were transduced with adenovirus harboring the FRET
sensor, Epac2-camps56 (a kind gift from Prof. Dermot Cooper, University of
Cambridge), before imaging using a Crest X-Light spinning disk system
coupled to a Nikon Ti-E base and ×10/0.4 NA objective. Excitation was delivered
at λ= 430–450 nm using a Lumencor Spectra X light engine. Emitted signals
were detected at λ= 460–500 and λ= 520–550 nm for Cerulean and Citrine,
respectively, using a Photometrics Delta Evolve EM-CCD. Imaging was
performed in HEPES–bicarbonate buffer, containing (in mmol/L) 120 NaCl, 4.8
KCl, 24 NaHCO3, 0.5 Na2HPO4, 5 HEPES, 2.5 CaCl2, 1.2 MgCl2, and 3–17
D-glucose. Vehicle (H2O), Exendin4(1–39) (10–20 nM), or Liraglutide (10 nM)
were applied at the indicated time points, with forskolin (10 µM) acting as a
positive control.
Immunostaining. LUXendin555 (250 nM) or LUXendin645 (50–250 nM) were
applied to cells or tissue for 60 min, before ﬁxation in 4% formaldehyde. Primary
antibodies were applied overnight at 4 °C in PBS+ 0.1% Triton+ 1% BSA. Sec-
ondary antibodies were applied in the same buffer for 1 h at room temperature,
before mounting on slides using Vectashield Hardset containing DAPI. Primary
antibodies were mouse monoclonal anti-GLP1R 1:30 (Iowa DHSB; mAb #7F38),
rabbit anti-insulin 1:500 (Cell Signaling Technology, #3014), mouse monoclonal
anti-glucagon 1:2000 (Sigma-Aldrich, #G2654), and mouse anti-somatostatin
1:5000 (Invitrogen, #14-9751-80). Secondary antibodies were goat anti-mouse
DyLight488, goat anti-mouse Alexa Fluor 568, and donkey anti-rabbit DyLight 488
1:1000. Images were captured using an LSM880 meta-confocal microscope.
DyLight488 and Alexa Fluor 568 were excited at λ= 488 nm and λ= 568 nm,
respectively. Emitted signals were detected at λ= 500–550 nm (DyLight 488) and
λ= 519–574 nm (Alexa Fluor 568). GLP1R surface expression was quantiﬁed vs.
total GLP1R expression, and normalized against Exendin4(1–39) controls.
Super-resolution microscopy. SRRF: MIN6 were treated with 250 nM LUX-
endin645 before live imaging, or ﬁxation and mounting on slides using Vectashield
Hardset containing DAPI. Imaging was performed using a Crest X-Light spinning
disk system in bypass (wideﬁeld) mode. Excitation was delivered at λ= 640/30 nm
through a ×60/1.4 NA objective using a Lumencor SPECTRA X light engine.
Emission was collected at λ= 700/75 nm using a Photometrics Delta Evolve
EMCDD. A 250–500 frame raw image sequence was captured (~2 min) before
ofﬂine super resolution radial ﬂuctuation (SRRF) analysis to generate a single
super-resolution snapshot using the NanoJ plugin for ImageJ (NIH)38.
STED microscopy: MIN6 cells were treated with 100, 200, and 400 nM
LUXendin651 before ﬁxation (4% paraformaldehyde, 20 min). Cells were mounted
in Mowiol supplemented with DABCO and imaged on an Abberior STED 775/595/
RESOLFT QUAD scanning microscope (Abberior Instruments GmbH, Germany)
equipped with STED lines at λ= 595 and λ= 775 nm, excitation lines at λ= 355,
405, 485, 561, and 640 nm, spectral detection, and a UPlanSApo ×100/1.4 oil
immersion objective lens. Following excitation at λ= 640 nm, ﬂuorescence was
acquired in the spectral window λ= 650–800 nm. For live-imaging, MIN6 cells
were seeded on 18 mm coverslips 24–48 h prior to treatment with 400 nM
LUXendin651 for 30–45 min before washing once in full medium. Coverslips were
transferred into a magnetic chamber (Chamlide CMB, Live Cell Instrument) and
washed once with HBSS buffer (Lonza, with additional 5 mM HEPES bubbled with
carbogen for 5 min and pH adjusted to 7.4 with NaOH), which was also used as
imaging buffer at 24 °C. Live imaging was performed within 45 min after
mounting.
Deconvolution was performed with Richardson–Lucy algorithm on Imspector
software. FWHM was measured on raw data and calculated using OriginPro
2017 software with Gaussian ﬁtting (n= 15 proﬁles). Minimum and maximum
intensity values refer to intensities after deconvolution for STED images and
smoothing with a 1-pixel lowpass Gaussian ﬁlter for confocal images. Spatial
GLP1R expression patterns were analyzed using the F- and G-functions, where F=
distance between an object of interest and its nearest neighbor, and G= distance
from a given position to the nearest object of interest (FIJI Spatial Statistic 2D/3D
plugin)57. Both measures were compared to a random distribution of the same
measured objects, with a shift away from the mean ± 95% conﬁdence intervals
indicating a non-random or more clustered organization (i.e. more space or smaller
distance between objects). Cells possessing highly concentrated GLP1R clusters
were identiﬁed based upon their ﬂuorescence above a threshold of the population
mean ﬂuorescence +1 s.d.
Single-molecule microscopy: For single-molecule experiments, CHO-K1-
SNAP_GLP1R cells were seeded onto 25 mm clean glass coverslips at a density of
3 × 105 per well. On the following day, cells were labeled in culture medium with
100 pM LUXendin645 or LUXendin651 for 20 min; this concentration avoids
labeling all GLP1R, which would otherwise preclude single-molecule analysis in a
stable cell line. At the end of the incubation, cells were washed 3 × 5min in culture
medium. Cells were then imaged at 37 °C in phenol-red free Hank’s balanced salt
Fig. 8 LUXendin645 labels human ESC-derived β-like cells. a LUXendin645 (LUX645) labels β-like cells in intact spheroids, which were differentiated
and cultured for 21 days. No signal is detected in undifferentiated human ES cells (day 0) or unlabelled β-like cells (-LUX645) (representative images from
n= 6 spheroids) (scale bar= 100 µm). b GLP1R gene expression in day 0 undifferentiated cells, day 21 differentiated β-like cells, and human islets (n= 3
donors). c LUXendin645 labelling is localized to strongly insulin (INS)-positive but not strongly glucagon (GCG)-positive areas (representative images
from n= 5–6 spheroids) (scale bar= 50 µm). d LUXendin645 (LUX) overlaps more with INS vs. GCG, as calculated using Manders’ M1 co-efﬁcient (n=
5–6 spheroids) (unpaired Student’s t-test). e Day 21 spheroid sections (5 µm) showing expression of INS and NKX6-1, conﬁrming a differentiated
phenotype (representative images from n= 4 spheroids) (scale bar= 100 µm). f FACS plots of day 21 β-like cells with and without LUXendin645
(LUX645) incubation. LUXendin645+ (LUX+) and LUXendin645− (LUX−) cells were sorted for qPCR. g GLP1R, NKX6-1, INS, and GCG gene expression in
sorted cells (n= 4 spheroids) (connecting bars indicate LUX+ and LUX− populations in the same samples) (paired Student’s t-test). LUXendin645 was
applied at 100 nM. Mean ± s.e.m. are shown. *P < 0.05, **P < 0.01 for all statistical tests. Source data are provided as a Source Data ﬁle.
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solution, using a custom built TIRF microscope (Cairn Research) based on an
Eclipse Ti2 (Nikon, Japan) equipped with an EMCCD camera (iXon Ultra, Andor),
637 nm diode laser, and a ×100 oil-immersion objective (NA 1.49, Nikon). Image
sequences were acquired with an exposure time of 60 ms.
Image sequences were analyzed with an automated particle detection software
(utrack) in the MATLAB environment40,58. To analyze the motion of receptors, the
time-averaged mean-squared displacement (TA-MSD)59 of individual trajectories
from TIRF image sequences was computed40. To calculate the diffusion coefﬁcient
(D), the TA-MSD data were ﬁtted with the following equation:
TAMSD tð Þ ¼ 4Dtα þ 4σ2err
where t indicates time, α is the anomalous diffusion exponent and σerr is a constant
offset for localization error. Only trajectories lasting at least 50 frames were
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analyzed (ntraj= 5057 for Cy5 and 8612 for SiR). Trajectories were then categorized
according to the diffusion parameters D and α. Particles with D < 0.01 μm2 s−α
were considered to be immobile. Normal diffusion was assigned to particles that
had D ≥ 0.01 μm2 s−α and 0.75 ≤ α ≤ 1.25. Sub-diffusion and super-diffusion were
assigned to particles with D ≥ 0.01 μm2 s−α and α < 0.75 or α > 1.25, respectively.
Brain labelling. Mice were injected subcutaneously with 100 pmol/g of LUX-
endin645 and left for two hours before terminal anaesthesia and transcardial
perfuse ﬁxation with 4% fresh formalin. Brains were serially sectioned at 30 µm and
mounted on slides before imaging, as above. Super-resolution snapshots (~140 nm
lateral resolution) were acquired using a Zeiss LSM880 equipped with an Airyscan
module and a ×63/1.2W objective. Brain clearing was carried out using the
3DISCO protocol60. Samples were suspended on a needle, before imaging using a
custom-built optical projection tomography (OPT) platform, with images collected
after excitation at λ= 470 and 660 nm. Images were reconstructed using custom-
written MATLAB scripts and visualized in Volocity (Perkin-Elmer).
Two-photon in vivo imaging. Female and male C57BL/6J mice 7–12 weeks of age
were used. Each mouse was anesthetized with isoﬂurane and a small, 1 cm vertical
incision was made at the level of the pancreas. The exposed organ was orientated
underneath the animal and pressed against a 50 mm glass-bottom dish for imaging
on an inverted microscope. Body temperature was maintained using heat pads and
heating elements on the objective. The mouse received Hoechst 33342 (1 mg/kg in
PBS) to label nuclei, a 150 kDa ﬂuorescein-conjugated dextran (1 mg/kg in PBS) to
label vasculature, and 75 μL of 30 µM LUXendin555 via retro-orbital IV injection.
Images were collected using a Leica SP8 microscope, equipped with a ×25/0.95 NA
objective and Spectra Physics MaiTai DeepSee mulitphoton laser. Excitation was
delivered at λ= 850 nm, with signals collected with a HyD detector at λ= 460/50,
λ= 525/50, λ= 624/40 nm for Hoechst, FITC, and LUXendin555, respectively.
Blood was collected from the tail vein prior to and 30 min after LUXendin555
injection, and glucose was measured using an AlphaTrak2 glucometer. All in vivo
imaging experiments were performed with approval and oversight from the
Indiana University Institutional Animal Care and Use Committee (IACUC).
Stem cell differentiation and gene expression analyses. WA01/H1 hESCs were
differentiated using the protocol published by Nair et al.61. Brieﬂy, dissociated H1
hESCs were plated on six-well plates at a density of 5.5 million cells in 5.5 mL
media per well. The plates were incubated at 37 °C and 5% CO2 on an orbital
shaker at 100 rpm to induce spheroid formation. After 24 h, six-step differentiation
was induced. Differentiation was stopped at day 21 and spheroids labelled with
LUXendin645, ﬁxed in 4% formaldehyde and co-stained with insulin and gluca-
gon. To conﬁrm differentiation, a subset of spheroids was parafﬁn-embedded,
sectioned at 5 µm and stained for insulin and NKX6-1. Primary antibodies were
guinea pig anti-insulin 1:500 (Dako Cytomation, #A0564), mouse monoclonal anti-
glucagon 1:2000 (Sigma-Aldrich, #G2654), and rabbit monoclonal anti-NKX6-1
(D8O4R) 1:400 (Cell Signaling, #54551). Secondary antibodies were donkey anti-
guinea pig FITC, donkey anti-mouse FITC, and donkey anti-rabbit Cy3 1:200
(Jackson Immuno Research Laboratories, #706-096-148, #715-096-150, #711-166-
152). The spheroids and sections were imaged using a Leica SP8 confocal micro-
scope with a ×20/0.75 IMM objective. Manders’ co-efﬁcient (Coloc 2 plugin for
FIJI) was used to quantify the extent of overlap of LUXendin645 signal with the
insulin or glucagon channels (M1).
nCounter gene expression assay (Nanostring, WA) was used to assess GLP1R
gene expression in hESCs, differentiated β-like cells, and human islets. The values
are normalized to six different housekeeping genes (B2M, GAPDH, GUSB, HPRT1,
POLR2A, and TBP). Human islets were obtained from Alberta Islet Distribution
Program. Sex, age, and BMI of each islet sample were: #1: Male, 53 y.o., 33.7 kg/m2,
#2: Female, 17 y.o., 22.7 kg/m2, #3: Male, 18 y.o., 22.9 kg/m2. WA01/H1 hESCs
were obtained under MTA from WiCell (Madison WI) and institutional use was
approved by the BCCHR/UBC Human Research Ethics Board (Approval # H09-
00676).
For FACS analysis, LUXendin-labelled spheroids were collected, incubated with
Accumax at 37 °C for 10 min and dissociated into single cells. CMRL with 1% BSA
was added, followed by ﬁltering through a 40-mm nylon ﬁlter. Cells were
centrifuged for 5 min at 200×g, washed with PBS, and resuspended in 500 µL of
PBS. LUXendin+ and LUXendin− cells were sorted into TRIzol for further qPCR
using a BD FACSAria IIu. RNA was isolated with TRIzol, DNase-treated with
Turbo DNAse Free, and reverse transcribed with Superscript III. TaqMan qPCR
was performed and data were normalized by TBP. Primers used were: GLP1R
(forward [F], 5′-GTGCTATACATCCACTTCAGGG-3′; reverse [R], 5′-GCTCTG
GTTATCGCCTCTG-3′; and probe 5-TCCACCTGAACCTGTTTGCATCCT-3′),
NKX6-1 (F, 5′-TCGTTTGGCCTATTCGTTGG-3′; R, 5′-TGTCTCCGAGTCCTG
CTTC-3′; and probe 5-TGCTTCTTCCTCCACTTGGTCCG-3′), INS (F, 5′-CTA
GTGTGCGGGGAACG-3′; R, 5′-CACGCTTCTGCAGGGAC-3′; and probe 5-C
GGCGGGTCTTGGGTGTGTA-3′), GCG (F, 5′-GTCCAGATACTTGCTGTAGT
CAC-3′; R, 5′-ACGTTCCCTTCAAGACACAG-3′; and probe 5-ATGGCGCTTGT
CCTCGTTCATCT-3′), and TBP (F, 5′-GAGAGTTCTGGGATTGTACCG-3′; R,
5′-ATCCTCATGATTACCGCAGC-3′; and probe 5-TGGGATTATATTCGGCG
TTTCGGGC-3′).
Statistical analyses. Measurements were performed on discrete samples unless
otherwise stated. All analyses were conducted using GraphPad Prism software.
Unpaired or paired Student's t-test was used for pairwise comparisons. Multiple
interactions were determined using one-way or two-way ANOVA followed by
Bonferonni’s, Dunn’s, or Sidak’s posthoc tests (accounting for degrees of freedom).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
LUXendins are freely available for academic use. Glp1r(GE)−/−, GLU-YFP, and
GLP1RCre animals are subject to a Material Transfer Agreement. The source data
underlying Figs. 2a–c, g, k, 3b–f, 4f and h, 5e–g, 6c, 8b and d, and 9c–f and
Supplementary Figs. 12, 15, and 16 are provided as a Source Data ﬁle. Raw image ﬁles are
available upon reasonable request.
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